Results for tag: "Durvalumab"

Durvalumab is a monoclonal antibody used to treat non-small cell lung cancer (NSCLC). It is a type of immunotherapy, which works by targeting and blocking a protein called PD-L1. This protein is found on the surface of some cancer cells and helps them to evade the body’s immune system. By blocking PD-L1, durvalumab helps the body’s immune system to recognize and attack the cancer cells. Durvalumab is usually used in combination with other treatments, such as chemotherapy or radiation therapy. It is approved for use in patients with locally advanced or metastatic NSCLC who have not responded to other treatments. Durvalumab is a relatively new drug, and is still being studied in clinical trials to determine its effectiveness in treating other types of cancer. It is also being studied in combination with other drugs, such as chemotherapy and immunotherapy, to see if it can improve outcomes for patients with NSCLC. Some companies in the durvalumab market include AstraZeneca, Merck, and Bristol-Myers Squibb. These companies are researching and developing durvalumab for use in treating NSCLC and other types of cancer. Show Less Read more